Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.

Journal of hematology & oncology·2022

Same author

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.

Blood advances·2022

Same author

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

Cancers·2022

Same author

Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.

American journal of hematology·2022

Same author

Prediction for sustained deep molecular response for treatment-free remission.

Leukemia & lymphoma·2021

Same author

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Blood·2021

Search research articles

Related Experiment Video

Updated: May 22, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Adherence to BCR-ABL inhibitors: issues for CML therapy.

Elias Jabbour¹, Giuseppe Saglio, Jerald Radich

¹The University of Texas M.D. Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA. ejabbour@mdanderson.org

Clinical Lymphoma, Myeloma & Leukemia

|May 29, 2012

Summary

Patient adherence to lifelong chronic myeloid leukemia (CML) oral BCR-ABL inhibitor therapy is a significant concern. Poor adherence impacts treatment efficacy and increases costs, necessitating individualized and simplified treatment plans.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 22, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Area of Science:

Hematology
Pharmacology
Oncology

Background:

Chronic myeloid leukemia (CML) treatment has advanced with oral BCR-ABL inhibitors.
Lifelong therapy is often required for CML management.
Medication adherence is a critical challenge in managing chronic conditions like CML.

Purpose of the Study:

To highlight the importance of medication adherence in CML patients on BCR-ABL inhibitors.
To discuss the prevalence and consequences of nonadherence.
To identify factors influencing adherence and suggest strategies for improvement.

Main Methods:

Review of existing literature on CML treatment and medication adherence.
Analysis of factors contributing to nonadherence in CML patients.
Discussion of clinical implications of adherence and nonadherence.

Main Results:

Nonadherence is common in CML, affecting one-third or more of patients.
Reduced adherence to BCR-ABL inhibitors is linked to decreased treatment efficacy.
Nonadherence is associated with increased healthcare utilization and costs.

Conclusions:

Physicians must address and monitor factors influencing adherence, such as dose, toxicity, and concomitant medications.
Individualizing CML treatment and simplifying regimens can maximize patient adherence.
Optimizing adherence is crucial for long-term CML management and patient outcomes.